42 Result(s)

Article

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group

This study investigated changes in treatment modalities and outcomes of chronic myeloid leukemia in the chronic phase (CP-CML) after the approval of second-generation tyrosine kinase inhibitors (2G-TKIs) for f...

Noriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura… in International Journal of Hematology (2024)

Article

Macrophage depletion using clodronate liposomes reveals latent dysfunction of the hematopoietic microenvironment associated with persistently imbalanced M1/M2 macrophage polarization in a mouse model of hemophagocytic lymphohistiocytosis

Hemophagocytic lymphohistiocytosis (HLH), a hyperinflammatory syndrome, is caused by the incessant activation of lymphocytes and macrophages, resulting in damage to organs, including hematopoietic organs. Rece...

Takashi Koike, Katsuhiro Miura, Yoshihiro Hatta, Hideki Nakamura… in Annals of Hematology (2023)

Article

Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects

ABL1-tyrosine kinase inhibitors (TKIs) are an established treatment choice for patients with chronic myeloid leukemia in the chronic phase (CML-CP). However, effects of TKI dose modification have not been well...

Michihide Tokuhira, Yuta Kimura, Takayuki Tabayashi… in International Journal of Hematology (2023)

Article

Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation

Shun-ichi Kimura, Hiroaki Shimizu, Takuya Miyazaki… in Bone Marrow Transplantation (2023)

Article

A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma

Background Infusion-related reactions (IRRs) during rituximab administration are occasionally severe and remain problematic in oncology practice. Aim To establish a safer, risk-stratified rituximab protocol for p...

Daisuke Tsutsumi, Tatsuya Hayama… in International Journal of Clinical Pharmacy (2022)

Article

Stop** tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia

For patients with Philadelphia chromosome (Ph)-positive leukemia, there is no consensus regarding how long tyrosine kinase inhibitors (TKI) should be given or whether TKI could be stopped if TKI is administrat...

Hideki Nakasone, Shinichi Kako, Takehiko Mori… in Bone Marrow Transplantation (2021)

Article

Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group

This phase 1/2 study aimed to identify the maximum tolerated dose, the recommended phase 2 dose (RP2D), and efficacy of the clofarabine, etoposide, and cyclophosphamide combination regimen in adult patients wi...

Takeshi Saito, Yoshihiro Hatta, Fumihiko Hayakawa… in International Journal of Hematology (2021)

Article

JSH practical guidelines for hematological malignancies, 2018: I. leukemia—3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL)

Yoshihiro Hatta, Fumihiko Hayakawa, Etsuko Yamazaki in International Journal of Hematology (2020)

Article

MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy

The use of bortezomib in the clinic has significantly improved outcomes for patients with multiple myeloma (MM), even those harboring high-risk cytogenetic abnormalities or those classified in the high-risk ca...

Kazuya Kurihara, Noriyoshi Iriyama, Katsuhiro Miura, Yoshihito Uchino… in Medical Oncology (2019)

Article

Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database

This study investigated the incidence rate and features of vascular adverse events (VAEs) in Japanese patients with chronic myeloid leukemia (CML) who were treated with tyrosine kinase inhibitors (TKIs). The a...

Isao Fujioka, Tomoiku Takaku, Noriyoshi Iriyama, Michihide Tokuhira… in Annals of Hematology (2018)

Article

Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis

Treatment with a tyrosine kinase inhibitor (TKI) is the standard of care for patients with chronic myeloid leukemia (CML). The new-generation TKIs, nilotinib and dasatinib, are found to have deeper and faster ...

Noriyoshi Iriyama, Kei-Ji Sugimoto, Eriko Sato, Tomoiku Takaku… in Medical Oncology (2018)

Article

Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia

Although it is well known that platelet depletion is one of the major adverse events related to tyrosine kinase inhibitor (TKI) therapy, the effect of TKIs on thrombopoietin (TPO), a stimulating factor for thr...

Takashi Hamada, Noriyoshi Iriyama, Hiromichi Takahashi… in Clinical Drug Investigation (2018)

Article

Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors

We performed a retrospective study to evaluate the incidence of second malignancies (SMs) in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We analyzed data from 339 pa...

Tomonori Nakazato, Noriyoshi Iriyama, Michihide Tokuhira, Maho Ishikawa… in Medical Oncology (2018)

Article

Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase

ABL1-tyrosine kinase inhibitors (TKIs) have led to dramatic changes in treatment strategies for chronic myeloid leukemia in the chronic phase (CML-CP). However, clinical studies have highlighted increasing num...

Michihide Tokuhira, Yuta Kimura, Keiji Sugimoto, Tomonori Nakazato… in Medical Oncology (2018)

Article

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study

The objective of this prospective clinical trial (JALSG-STIM213, UMIN000011971) was to evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic myeloid leukemia (CML). CML pat...

Naoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura… in International Journal of Hematology (2018)

Article

A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior

Mantle cell lymphoma (MCL) is a B cell neoplasm characterized by cyclin D1 overexpression; its prognosis is poor, especially when it exhibits a blastoid morphology. Cyclin D1-negative MCL is rare, and its path...

Daisuke Kurita, Kengo Takeuchi, Sumiko Kobayashi, Atsuko Hojo… in Virchows Archiv (2016)